Cost-effectiveness of bladder cancer screening

Yair Lotan, Robert S. Svatek

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Bladder cancer is the fourth most common cancer in men and 25% of patients present with advanced disease resulting in a poor prognosis. Urine-based tests, including evaluation for blood in the urine or tumor markers, may allow early detection of cancer with resultant improved survival. Studies need to be performed to evaluate the feasibility and cost-effectiveness of screening high-risk populations such as smokers.

Original languageEnglish (US)
Pages (from-to)627-632
Number of pages6
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Issue number6
StatePublished - Dec 2007
Externally publishedYes


  • Bladder cancer
  • Cost-effectiveness
  • Screening

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Health Policy


Dive into the research topics of 'Cost-effectiveness of bladder cancer screening'. Together they form a unique fingerprint.

Cite this